11101 related articles for article (PubMed ID: 11389822)
1. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.
Eggermont AM; ten Hagen TL
Curr Oncol Rep; 2001 Jul; 3(4):359-67. PubMed ID: 11389822
[TBL] [Abstract][Full Text] [Related]
2. Current uses of isolated limb perfusion in the clinic and a model system for new strategies.
Eggermont AM; de Wilt JH; ten Hagen TL
Lancet Oncol; 2003 Jul; 4(7):429-37. PubMed ID: 12850194
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
[TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
[TBL] [Abstract][Full Text] [Related]
7. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities.
Grünhagen DJ; de Wilt JH; ten Hagen TL; Eggermont AM
Nat Clin Pract Oncol; 2006 Feb; 3(2):94-103. PubMed ID: 16462850
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity.
Bickels J; Manusama ER; Gutman M; Eggermont AM; Kollender Y; Abu-Abid S; Van Geel AN; Lev-Shlush D; Klausner JM; Meller I
Eur J Surg Oncol; 1999 Oct; 25(5):509-14. PubMed ID: 10527599
[TBL] [Abstract][Full Text] [Related]
9. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; van Geel AN; Eggermont AM
Cancer; 2006 Jan; 106(1):156-62. PubMed ID: 16323177
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
van Ijken MG; van Etten B; de Wilt JH; van Tiel ST; ten Hagen TL; Eggermont AM
J Immunother; 2000; 23(4):449-55. PubMed ID: 10916754
[TBL] [Abstract][Full Text] [Related]
12. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Komdeur R; Plaat BE; Hoekstra HJ; Molenaar WM; Hollema H; van den Berg E; Mastik MF; van der Graaf WT
Cancer; 2001 May; 91(10):1940-8. PubMed ID: 11346877
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
[TBL] [Abstract][Full Text] [Related]
14. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs].
Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM
Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515
[TBL] [Abstract][Full Text] [Related]
15. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.
Verhoef C; de Wilt JH; Grünhagen DJ; van Geel AN; ten Hagen TL; Eggermont AM
Curr Treat Options Oncol; 2007 Dec; 8(6):417-27. PubMed ID: 18066703
[TBL] [Abstract][Full Text] [Related]
17. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
[TBL] [Abstract][Full Text] [Related]
18. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
Jakob J; Hohenberger P
Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
[TBL] [Abstract][Full Text] [Related]
19. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
[TBL] [Abstract][Full Text] [Related]
20. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
